Literature DB >> 10885643

Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders.

P S Wang1, J C West, T Tanielian, H A Pincus.   

Abstract

Up-to-date data are needed on the types of treatments used by psychiatrists and the reasons for use of particular treatments. Using 1997 American Psychiatric Association (APA) Practice Research Network (PRN) Study data on patients with schizophrenia and other psychotic disorders, we identified the characteristics of antipsychotic medications (APMs) currently being prescribed and factors associated with the use of particular regimens. In this study population, use of the newer APMs, including risperidone, olanzapine, and clozapine, has increased rapidly and now accounts for over one-half of all APM use. Other intriguing findings include the fact that one-sixth of patients with schizophrenia and other psychotic disorders are concurrently treated with two or more APMs. Factors associated with being prescribed one of the newer APMs risperidone or olanzapine include being elderly, having more education, being white, having psychiatric comorbidity, and making fewer recent visits to a psychiatrist. The APA PRN Study data are an important new resource for mental health services researchers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885643     DOI: 10.1093/oxfordjournals.schbul.a033465

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  18 in total

Review 1.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

Review 2.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

Review 3.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

4.  Antipsychotic combinations for schizophrenia.

Authors:  Nicola Maayan; Karla Soares-Weiser; Jun Xia; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2011

5.  Communities of color? Client-to-client racial concordance in the selection of mental health programs for Caucasians and African Americans.

Authors:  Naoru Koizumi; Aileen B Rothbard; Tony E Smith; Jeremy D Mayer
Journal:  Health Care Manag Sci       Date:  2011-05-25

6.  Multi-receptor drug design: Haloperidol as a scaffold for the design and synthesis of atypical antipsychotic agents.

Authors:  Kwakye Peprah; Xue Y Zhu; Suresh V K Eyunni; Vincent Setola; Bryan L Roth; Seth Y Ablordeppey
Journal:  Bioorg Med Chem       Date:  2011-12-22       Impact factor: 3.641

7.  The effect of income and race on quality of psychiatric care in community mental health centers.

Authors:  Eri Kuno; Aileen B Rothbard
Journal:  Community Ment Health J       Date:  2005-10

8.  Antipsychotic Use Pattern in People with Psychotic Disorder Living in Board and Care Facilities.

Authors:  Etem Erdal Ersan; Mustafa Yildiz
Journal:  Noro Psikiyatr Ars       Date:  2015-06-01       Impact factor: 1.339

Review 9.  [Augmenting atypical antipsychotic medications with clozapin].

Authors:  M Zink; H Dressing
Journal:  Nervenarzt       Date:  2005-09       Impact factor: 1.214

10.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.